In 2025 AbbVie outpaced the broader healthcare sector with revenue growth of approximately 9% year-over-year, driven by strong sales of its immunology portfolio. Skyrizi and Rinvoq collectively contributed over $12 billion in revenue, effectively compensating for the Humira patent expiration in 2023. Earnings per share for the year exceeded consensus estimates by 7%, supported by cost synergies from recent acquisitions and operating margins near 45%, up from 42% in the prior year.

Despite last year’s strength, AbbVie’s forward price-to-earnings ratio stands close to 21x, well above its five-year average of 17x. Potential headwinds include pricing concessions linked to most-favored-nation agreements that could compress gross margins by 100–150 basis points, as well as a broader market rotation favoring cyclicals over defensive healthcare names. Analysts project earnings growth slowing to mid‐single digits in 2026, placing a premium on near-term execution and pipeline progress.

AbbVie’s robust pipeline, featuring 15 late-stage assets across immunology, neuroscience and oncology, underpins a long-term revenue growth forecast of 6–8% annually. The company’s dividend track record—54 consecutive years of increases—ranks it among Dividend Kings, with a current yield near 2.9%. At a projected compound annual total return of 10.5% over a 30-year horizon, AbbVie’s combination of cash flow generation, pipeline depth and shareholder distributions positions it as a core holding for investors focused on income and capital appreciation.